Rekvina Laboratories Approves Q2 Results and Appoints New Company Secretary
Rekvina Laboratories Ltd 路 Change in Management 路 13 Nov 2026, 11:45 pm
Rekvina Laboratories Approves Q2 Results and Appoints New Company Secretary Rekvina Laboratories' Board of Directors met on 13th Nov'26 to approve the un-audited standalone and consolidated financial results along with the Limited Review Reports for the quarter and half-year ended 30th Sep'26. The board also reviewed the Regulation 32 statement on deviation or variation of funds. Additionally, Ms. Bhagyshree Manojbhai Kandoi was appointed as Company Secretary and Compliance Officer, effective 16th Nov'26.
Original exchange filing (PDF)
More announcements from Rekvina Laboratories Ltd
- Reg. 32 Statement of Deviation & Variation 路 13 Nov 2026
- Financial Result for QTR2 路 13 Nov 2026
- Outcome of Board Meeting 路 13 Nov 2026
- Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Financial Result for QTR2 路 13 Nov 2026
- Intimation regarding Temporary Shutdown of Manufacturing Facility for Renovation, Upgradation and Installation of an Additional Vial Manufacturing Line. 路 27 Oct 2026
- Appointment of Mr. Subrata Samanta as a Chief Financial officer of the company with effect from 07.10.2026. 路 08 Oct 2026
- AGM Voting Results along-with Scrutinizer Report on E-Voting 路 30 Sept 2026
- Summary of Proceeding of Annual General Meeting 路 29 Sept 2026
